2-Deoxy-D-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers in Vivo

Cancer Research

Volumn 64, Issue 1, 2004, Pages 31-34

  Maschek, Gregory ^a   Savaraj, Niramol ^a   Priebe, Waldemar ^b   Braunschweiger, Paul ^a   Hamilton, Kara ^a   Tidmarsh, George F ^c   De Young, Linda R ^c   Lampidis, Theodore J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Threshold Pharmacenticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYGLUCOSE; DOXORUBICIN; PACLITAXEL;

ANAEROBIC GLYCOLYSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL DIVISION; CELL GROWTH; CELL HYPOXIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; SOLID TUMOR; SURVIVAL RATE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYGLUCOSE; DOXORUBICIN; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; OSTEOSARCOMA; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 1642494855     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-3294     Document Type: Article

References (20)

1. Warburg, O. H. The Metabolism of Tumours. London: Constable and Co. Ltd., 1930.
2. Flier, J. S., Mueckler, M. M., Usher, P., and Lodish, H. F. Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science (Wash. DC), 235: 1492-1495, 1987.
3. Semenza, G. L., and Wang, G. L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythroprotein gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol., 12: 5447-5454, 1992.
4. 2 tension. Proc. Natl. Acad. Sci. USA. 92: 5510-5514, 1995.
5. Maxwell, H. P., Pugh, C. W., and Ratcliffe, P. J. Activation of the HIF pathway in cancer. Curr. Opin. Genet. Dev., 11: 293-299, 2001.
6. Bush, R. S., Jenkin, R. D. T., and Allt, W. E. C. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer. 37 (Suppl. 3): 302, 1978.
7. Shannon, A. M., Bouchier-Hayes, D. J., Condron, C. M., and Toomey, D. Tumor hypoxia, chemotherapeutic resistance and hypoxia-related therapies. Cancer Treat. Rev., 29: 297-307, 2003.
8. Teicher, B. A. Hypoxia and drug resistance. Cancer Metastasis Rev., 13: 513-518, 1994.
9. Hu, Y. P., Moraes, C., Suvaraj, N., Priebe, W., and Lampidis, T. J. Rho (0) Tumor cells: a model for studying whether mitochondria are targets for rhodamine 123, doxorubicin and other drugs. Biochem. Pharmacol., 60: 1897-1905, 2000.
10. Liu, H., Hu, Y. P., Savaraj, N., Priebe, W., and Lampidis, T. J. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry, 40: 5542-5547, 2001.
11. Liu, H., Hu, Y. P., Savaraj, N., Priebe, W., and Lampidis, T. J. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors a strategy for solid tumor therapy (Model C). Biochem. Pharmacol., 64: 1746-1751, 2002.
12. Wang, J., Lou, P., Lesniewski, R., and Henkin, J. Paclitaxel at ultra low concentrations inhibits angiogenesis without affecting cellular microtubule assembly. Anticancer Drugs, 14: 13-19, 2003.
13. Van Hensbergen, Y., Broxterman, H. J., Elderkamp, Y. W., Lankelma, J., Beers, J. C., Heijn, M., Boven, E., Hoekman, K., and Pinedo, H. M. A doxorubicin-CNGRC-peptide conjugate with prodrug properties. Biochem. Pharmacol., 63: 897-908, 2002.
14. Blagosklonny, M. V., An, W. G., Romanova, L. Y., Trepel, J., Fojo, T., and Neckers, L. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem., 273: 11995-11998, 1998.
15. Mabjeesh, N. J., Escuin, D., LaVallee, T. M., Pribluda, V. S., Swartz, G. M., Johnson, M. S., Willard, M. T., Zhong, H., Simons, J. W., and Giannakakou, P. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell, 4: 363-375, 2003.
16. Yamada, M., Tomida, A., Yun, J., Cai, B., Yoshikawa. H., Taketani, Y., and Tsuruo, T. Cellular sensitization to cisplatin and carboplatin with decreased removal of platinum-DNA adduct by glucose-regulated stress. Cancer Chemother. Pharmacol., 44: 59-64, 1999.
17. Kaplun, O., Navon, G., Lyon, R. C., Faustino, P. J., Straka, E. J., Cohen, J. S. Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism. Cancer Res., 50: 544-551, 1990.
18. Shen, J., Hughes, C., Chao, C., Cai, J., Bartels, C., Gessner, T., and Subjeck, J. Coinduction of glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc. Natl. Acad. Sci. USA, 84: 3278-3282, 1987.
19. Sauna, Z. E., Smith, M. M., Muller, M., Kerr, K. M., and Ambudkar, S. V. The mechanism of action of multidrug-resistance-linked P-glycoprotein. J. Bioenerg. Biomembr., 33: 481-491, 2001.
20. Georges, E., Sharom, F. J., and Ling, V. Multidrug resistance and chemosensitization: therapeutic implications for cancer chemotherapy. Adv. Pharmacol., 21: 185-220, 1990.